Nicolini, Franck E <br/><br/>
The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.  [electronic resource] 

 -  Clinical lymphoma, myeloma & leukemia  Oct 2010 
 - 394-9 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2152-2669 
<br/><br/><label>Standard No.: </label>10.3816/CLML.2010.n.073  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Drug Resistance, Neoplasm<br/>Female<br/>Fusion Proteins, bcr-abl--antagonists & inhibitors<br/>Harringtonines--therapeutic use<br/>Homoharringtonine<br/>Humans<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Protein Kinase Inhibitors--therapeutic use<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Pyrimidines--therapeutic use